Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9599 posts found.

Vaccine image

Pfizer shares new data from phase 2 trial for GBS maternal vaccine candidate

July 20, 2023 Research and Development Immunology, Pfizer, Vaccine, clinical trial

Pfizer has announced new data from its phase 2 study which assessed its hexavalent capsular polysaccharide (CPS) conjugate Group B …
News
alzheimers_brain

Eli Lilly shares results from phase 3 trial of donanemab for Alzheimer’s treatment

July 18, 2023 Research and Development Alzheimer's, Eli Lilly, Neurology, clinical trial, donanemab

Eli Lilly has presented full results from the phase 3 TRAILBLAZER-ALZ 2 study which assessed donanemab for the treatment of …
News
1200px-vaccine_image_1_1

FDA approves AstraZeneca’s drug to prevent RSV in babies and young children

July 18, 2023 Research and Development AstraZeneca, FDA, Immunology, RSV, Vaccine, paediatrics

The US Food and Drug Administration (FDA) has announced that it has approved Beyfortus (nirsevimab-alip) for the prevention of respiratory …
News

Alnylam shares positive results from phase 1 trial

July 17, 2023 Research and Development ALN-APP, Alnylam, Alzheimer's disease, Cerebral Amyloid Angiopathy, Neurology, clinical trial

Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of its phase 1 study of …
News

Recursion and NVIDIA partner for AI-enabled drug discovery developments

July 13, 2023 Research and Development AI, Pharmacy, Recursion, drug discovery

Clinical stage biotech company Recursion has announced a $50m investment by NVIDIA, intended to accelerate the development of its AI …
News
needle-1291170_960_720

Genentech shares results from phase 3 trial for MS treatment

July 13, 2023 Research and Development Genentech, MS, Neurology, Ocrevus, clinical trial

Genentech has announced positive results from its phase 3 OCARINA II trial which assessed Ocrevus (ocrelizumab) as a twice-a-year, ten-minute …
News

Innate Pharma doses first patient in relapsed/refractory multiple myeloma trial

July 11, 2023 Research and Development Innate Pharma, Oncology, Sanofi, clinical trial, multiple myeloma

Innate Pharma has announced that the first patient has been dosed in its Sanofi-sponsored phase 1/2 clinical trial, which aims …
News
eye2

Astellas and 4D Molecular Therapeutics enter license agreement for rare ophthalmic targets

July 11, 2023 Research and Development 4D Molecular Therapeutics, AAV vectors, Astellas Pharma, Opthalmology, ophthalmology

Astellas Pharma and 4D Molecular Therapeutics (4DMT) have announced a license agreement under which Astellas has the right to use …
News

OSE Immunotherapies’ UC drug gets DSMB positive recommendation

July 6, 2023 Research and Development EMA, Gastrointestinal tract, OSE Immunotherapeutics, ulcerative colitis

French biotech company OSE Immunotherapeutics has announced that its Ulcerative Colitis (UC) trial’s Independent Drug Safety Monitoring Board (DSMB) has provided …
News

FDA grants Priority Review for Astellas Pharma’s BLA for cancer drug

July 6, 2023 Research and Development Astellas Pharma, Biologics License Application, FDA, GEJ, Oncology

Japanese pharmaceutical company Astellas Pharma has announced that the US Food and Drug Administration (FDA) has granted Priority Review for …
News

Skyline Therapeutics receives FDA clearance of IND for candidate for neovascular age-related macular degeneration

July 5, 2023 Research and Development FDA, IND, Opthalmology, Skyline Therapeutics, neovascular age-related macular degeneration

Skyline Therapeutics has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application …
News

Amsterdam UMC’s new drug doubles remission rates in patients with ulcerative colitis

July 4, 2023 Research and Development Amsterdam UMC, Gastrointestinal tract, mirikizumab, ulcerative colitis

A new drug, being investigated by Amsterdam UMC along with colleagues at various universities, has been shown to be effective …
News
brainss

Sosei Heptares announces first subject dosed in phase 1 trial for schizophrenia therapy

July 3, 2023 Research and Development HTL'149, Neurology, Sosei Heptares, clinical trial, schizophrenia

Sosei Heptares has announced that it has dosed its first patient in its phase 1 trial evaluating HTL0048149 (HTL’149), a …
News

Astellas establishes open innovation hub for tumour microenvironment research

June 29, 2023 Research and Development Astellas Pharma, Mitsui Fudosan, Oncology, open innovation hub, tumour microenvironment

Astellas Pharma and Mitsui Fudosan have announced that Astellas plans to establish a tumour microenvironment (TME) open innovation hub, intended …
News

Anavex Life Sciences and Partex NV Group announce AI-based strategic partnership to enhance patient experience

June 28, 2023 Research and Development AI, Anavex Life Sciences, Partex NV Group, Pharmacy, patient experience

US-based clinical-stage biopharmaceutical company Anavex Life Sciences and German digital pharma platform Partex NV Group have announced a strategic partnership …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026